Genetic Advancements in AMD:
A Glimpse at the Future -page 18| November 2010
Anti-VEGF therapy is the current standard of care for
the treatment of wet AMD. But, even as remarkable as
anti-VEGF treatment is, there are some drawbacks.
Fortunately, current and ongoing genetic research
has helped us to better understand the intricate disease
processes associated with dry AMD development. In the
very near future, these findings may ultimately lead to
the production of several cutting-edge pharmaceutical
agents that specifically target the genes responsible for
macular degeneration.
Click Here to Read More
